Filing Flows › Rigel Pharmaceuticals (RIGL) › Q4 2025
Rigel Pharmaceuticals (RIGL) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 3, 2026
Rigel Pharmaceuticals (RIGL) reported revenue of $69.8M for the fourth quarter 2025 (Q4 2025), +21% from a year earlier and +0.5% from the quarter before. Operating margin was 33.2%, net earnings $268M (384.0% of revenue).
Rigel Pharmaceuticals, Q4 2025: revenue $69.8M (+21% year over year), operating margin 33.2%, net earnings $268M, operating cash flow $22.0M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $69.8M | +0.5% | +21% |
| Operating profit | $23.2M | -18% | +39% |
| Net earnings | $268M | +861% | 19× |
| Operating cash flow | $22.0M | -9% | +52% |
What changed
Revenue was $69.8M in Q4 2025, up 21% year over year and roughly flat from the previous quarter. Product sales, net was the largest line at 94% of revenue.
Operating profit was $23.2M, a 33.2% margin (up 4.3 points year over year). Of the extra revenue versus a year earlier, 53% reached operating profit, above the 29% margin then. Total costs grew 14% against revenue growth of 21%. The fastest-growing cost line was Research & development (+90%). Net earnings were $268.1M, up 1769% year over year. The tax line was a benefit of $245.4M on pre-tax earnings of $22.7M.
Operating cash flow was $22.0M (up 52% year over year), 8% of net earnings. Non-cash charges added back $601K of depreciation and amortization and $2.7M of share-based compensation. Working capital and other items used $249.4M. Capital expenditures of −$12K left free cash flow of $22.0M.
Questions
What was Rigel Pharmaceuticals' revenue in the fourth quarter 2025?
Rigel Pharmaceuticals (RIGL) reported revenue of $69.8M for the fourth quarter 2025 (Q4 2025), +21% from a year earlier and +0.5% from the quarter before.
Was Rigel Pharmaceuticals profitable in the fourth quarter 2025?
Operating profit was $23.2M (33.2% of revenue) and net earnings $268M.